Overview
Akoya Biosciences, now part of Quanterix, provides end-to-end spatial biology platforms including PhenoCycler (formerly CODEX) for high-parameter tissue analysis with over 40 markers and Phenoptics for translational and clinical research. These solutions support biomarker discovery, immuno-oncology drug development, and precise therapies from discovery to clinical trials. The platforms enable spatial phenotyping to understand complex diseases like cancer.
Frequently asked questions
- What spatial biology platforms does Akoya offer?
- Akoya offers PhenoCycler (formerly CODEX) for assessing over 40 markers in biomarker discovery and Phenoptics for assay robustness in translational and clinical research.
- What applications are Akoya's solutions used for?
- The platforms support high-parameter tissue analysis for immuno-oncology, drug development, and understanding complex diseases like cancer from discovery through clinical trials.
- Who acquired Akoya Biosciences and when?
- Quanterix completed the acquisition of Akoya Biosciences on July 8, 2025, creating an integrated platform for blood and tissue biomarker detection.